TRxADE Health (NASDAQ: MEDS), a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has entered into a securities purchase agreement with a single institutional investor. The agreement outlines the purchase of approximately $1.8 million of MEDS common stock, or prefunded warrants in lieu thereof, comprising a registered direct offering as well as warrants to purchase common stock in a concurrent private placement. Together, the purchase price for one share of common stock (or prefunded warrant) along with the associated warrants will total $1.15. As outlined in the agreement, TRxADE will sell 1,521,740 shares of common stock, or prefunded warrants in lieu thereof. In addition, TRxADE has agreed to a private placement; the company will issue warrants to purchase up 2,663,045 shares of common stock with an exercise price of $1.50 per share. The company anticipates the offering to close on or about Oct. 7, 2022, with Maxim Group LLC acting as sole placement agent for the offering.
To view the full press release, visit https://ibn.fm/XpA6s
About TRxADE Health Inc
TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug procurement marketplace serving more than 13,815 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services and televet services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
